AGAlexander Grunenberg

Alexander Grunenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Grunenberg has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatic Surgery in Alveolar Echinococcosis: Long-Term Outcomes and Practical Recommendations

    by Lynn Peters, Maria Leuchtner, Wanjie Jiang, Anna-Lena Allgäuer, Alexander Grunenberg, J. Benjamin Hagemann, Andreas Hillenbrand, Marko Kornmann, Beate Grüner

    Background: Alveolar echinococcosis (AE) is an infiltrative parasitic liver disease. Surgery remains preferred when feasible, but patient selection and the implications of resection margins remain uncertain. Methods: We retrospectively analysed 231 surgically treated AE patients first presenting at our centre between 1992 and 2021. A curative outcome required no recurrence on cross-sectional imaging and no ongoing benzimidazole therapy at last follow-up (≥2 years after R0; ≥4 years after R1). Kaplan–Meier analyses assessed recurrence-free survival (R0/R1) and progression-free survival (R2). Results: R0, R1, and R2 accounted for 42.4%, 19.9%, and 25.1%, respectively. Cure rates were 95.2% (R0) and 88.2% (R1) at ≥4 years post-surgery (p = 0.240). Estimated 10-year recurrence-free survival was 95.1% (R0) and 87.0% (R1; p = 0.183). After R2 resection, 84.0% had stable and 16.0% progressive residual disease. Extensive hepatic involvement (P4) was associated with lower cure rates (p < 0.001). Conclusions: An R1 margin does not preclude long-term cure and may represent an acceptable surgical endpoint in selected patients with postoperative benzimidazole therapy and imaging surveillance. Planned R2 resections should generally be avoided without specific clinical indications. In advanced disease or when macroscopic residual disease is anticipated, the benefits of surgery should be carefully weighed against medical treatment.

  • Open Access

    Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry

    by Alexander Grunenberg, Birgit Schmelzle, Jacqueline Gökeler, Heike Mund, Andreas Viardot, Jens Dreyhaupt, Gabriele Nagel, Marcel Reiser, Thomas Gabrysiak, Friederike Braulke, et al.

  • Open Access

    A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

    by Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, et al.

    Background: Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goals in this palliative setting is to develop chemotherapy-free treatments, which approach the efficacy of immunochemotherapies, but avoid chemotherapy associated toxicity in this often elderly patient population. The PI3K inhibitor copanlisib has recently shown remarkable clinical activity in refractory or relapsed indolent B–cell lymphomas, among them MZL. Based on these data, copanlisib monotherapy was granted breakthrough designation by the FDA for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies. However, data are still limited in particular for MZL. Based on this, the COUP-1 trial aims at testing the toxicity and efficacy of copanlisib in combination with rituximab in treatment naive and relapsed MZL. Methods: COUP-1 is a prospective, multicenter, single-arm, open-label, non-randomized phase II trial of 6 cycles (28 days cycle) of copanlisib (60 mg intravenous day 1, 8, 15) and rituximab (375 mg/m2 intravenous day 1) in the induction phase followed by a maintenance phase of copanlisib (d1, d15 every 4 weeks for a maximum of 12 cycles) and rituximab (d1 every 8 weeks for a maximum of 12 cycles) in patients aged ≥18 years with previously untreated or relapsed MZL in need of treatment. A total of 56 patients are to be enrolled. Primary endpoint is the complete response (CR) rate determined 12 months after start of induction therapy. Secondary endpoints include the overall response (OR) rate, progression free survival (PFS), overall survival (OS), safety and patient related outcome with quality of life. The study includes a translational bio-sampling program with the prospect to measure minimal residual disease. The study was initiated in November 2019. Discussion: The COUP-1 trial evaluates the efficacy and toxicity of the treatment of copanlisib in combination with rituximab in patients with MZL and additionally offers the chance for translational research in this heterogenous type of lymphoma. Trial registration: ClinicalTrials.gov: NCT03474744. Registration date: 03/23/2018.


  • Neue Entwicklungen beim Morbus Waldenström

    by Alexander Grunenberg, Christian Buske

    Der Morbus Waldenström ist eine seltene Subentität in der Gruppe der indolenten B-Zell-Lymphome. Derzeitiger Standard in der Therapie ist eine Rituximab- / Chemotherapie. In letzter Zeit wurden bei Patienten mit einem Morbus Waldenström eine Reihe von genetischen Veränderungen entdeckt, von denen die MYD88 Mutation bei über 90 % der Patienten vorkommt und bei der Diagnose der Erkrankung helfen kann. Mit der Einführung des oralen Bruton-Tyrosinkinaseinhibitor Ibrutinib steht eine effektive chemotherapiefreie Behandlung zur Verfügung. Waldenström’s Macroglobulinemia (WM) is a rare subtype of B-cell lymphoma with mostly indolent course. Until now the backbone of therapy is still Rituximab / Chemotherapy. In recent years whole genome sequencing has revealed a number of genetic mutations, among them mutations of the MYD88 gene which occurs in over 90 % of patients and helps to validate diagnosis of WM in difficult cases. With the introduction of ibrutinib, an oral bruton-tyrosine-kinase inhibitor, an effective chemotherapy-free treatment option is available.